Search | Clinical Trials Finder

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 21 more

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 538 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 23
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 16 more

Conditions: Hemophilia a, Hemophilia B
Interventions: No Intervention; Other
Lead sponsor: ApcinteX Ltd; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Greenville, South Carolina

Conditions: Menorrhagia, Blood Coagulation Disorders, Blood Platelet Disorders, Von Willebrand Disease, Hematologic Disease
Interventions: Tranexamic Acid, Desmopressin Acetate; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 6
States / cities: Atlanta, Georgia • East Lansing, Michigan • Rochester, Minnesota + 3 more

Conditions: Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Pemetrexed; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Von Willebrands Disease
Interventions: Not listed
Lead sponsor: Jonathan Roberts; Other
Eligibility: 2 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Edema, Ecchymosis
Interventions: Hyperbaric oxygen treatment, Air sham; Drug
Lead sponsor: Restorix Research Institute, LLLP; Other
Eligibility: 40 Years to 85 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Issaquah, Washington

Conditions: Von Willebrand Disease, Type 3
Interventions: Von Willebrand Factor Concentrates, Von Willebrand Factor Concentrates and Factor VIII Concentrates, Factor VIII Concentrates, Recombinant Activated Factor VII, Activated Prothrombin Complex Concentrate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Sacramento, California • Minneapolis, Minnesota • St Louis, Missouri

Conditions: Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety, Gastrointestinal Hemorrhage, Hepatomegaly, Lymphadenopathy, Macroglossia, Nausea, Primary Systemic Amyloidosis, Purpura, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis
Interventions: Isatuximab, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 345
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Burbank, California + 234 more

Conditions: Von Willebrand Diseases, Postpartum Hemorrhage
Interventions: Recombinant Von Willebrand factor, Tranexamic Acid Injection [Cyklokapron]; Drug
Lead sponsor: Nicoletta C Machin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Immune Thrombocytopenic Purpura (ITP)
Interventions: Mezagitamab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 21
States / cities: Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 17 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: decitabine, romidepsin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Senile Purpura, Bateman's Purpura
Interventions: Broad Band Light (BBL); Device
Lead sponsor: Siperstein Dermatology; Other
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Hemophilia B
Interventions: verbrinacogene setparvovec; Genetic
Lead sponsor: Spur Therapeutics; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan

Conditions: Hemophilia A
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Conditions: Blood Coagulation Disorders, Acute Major Bleeding
Interventions: Beriplex® P/N (Kcentra), Fresh frozen plasma; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Franciso, California + 33 more

Conditions: Wiskott-Aldrich Syndrome
Interventions: Retrovirus-mediated gene transfer; Biological
Lead sponsor: David Williams; Other
Eligibility: 3 Months to 35 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Congenital Bleeding Disorder, Haemophilia B
Interventions: nonacog beta pegol; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Cincinnati, Ohio • Portland, Oregon • Richmond, Virginia

Conditions: VWD - Von Willebrand's Disease
Interventions: Not listed
Lead sponsor: VWD Connect Foundation; Other
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Wellington, Florida

Conditions: Hemophilia A
Interventions: Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 6 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Conditions: Venous Thrombosis, Venous Insufficiency
Interventions: Not listed
Lead sponsor: University of Vermont; Other
Eligibility: 40 Years to 79 Years
Enrollment: 2,211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Hemophilia A, Factor VIII
Interventions: Eloctate, Adynovate, Emicizumab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Primary Immune Thrombocytopenia
Interventions: efgartigimod; Biological
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Ocala, Florida • Iowa City, Iowa + 1 more

Conditions: Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
Interventions: Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma; Drug · Biological
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia

Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

Treatment and Management of Women With Bleeding Disorders

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)

Effects of Hyperbaric Oxygen Therapy on Surgical Wound Healing

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders

Broad Band Light for the Treatment and Prevention of Senile Purpura

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

Inhibitor Development in Patients With Hemophilia A Undergoing Surgery

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

The Severe Von Willebrand Disease (sVWD) Patient Registry

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients

Evaluating the Relationship Between Blood Clotting Disorders, Inflammation, and Obesity in Individuals With Venous Disorders and Post-Thrombotic Syndrome

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

FFP Versus PCC in Intracranial Hemorrhage